Trial Profile
A two-period, randomized, open-label, parallel group, multiple-probe drug interaction study to determine the effects of NCE [relacatib] on the metabolism of CYP450 probe substrates in healthy postmenopausal women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Relacatib (Primary)
- Indications Cancer metastases; Osteoarthritis; Postmenopausal osteoporosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Aug 2007 New trial record.